Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib + cobimetinib beyond focal progression versus second-line therapy in BRAF V600-mutant metastatic melanoma
2017-003038-98Phase 2Completed
- Sponsor
- Intergruppo Melanoma Italiano
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of vemurafenib, cobimetinib, nivolumab and pembrolizumab in melanoma (2 arms), sponsored by Intergruppo Melanoma Italiano. Primary endpoint: Overall survival in patients with focal progression. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2017-003038-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003038-98.